All In Biotech

Drug Trial Radar · NCT02956317

A Randomized Study to Evaluate the Safety and Efficacy of Various Doses of STP705 in Subjects With Hypertrophic Scar

A Randomized, Double-Blind, Within-Subject Placebo Controlled Study to Evaluate the Safety and Efficacy of Various Doses of STP705 Administered as Intradermal Injection in Subjects With Hypertrophic Scar.

Last checked: Nov 19, 2026Latest source record: Nov 24, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

25

Actual

Start

Jan 2017

Primary completion

Jan 2018

Study completion Jan 2018

Sponsor

Lead sponsor
SirnaomicsIndustry
Sponsor type
Industry
First posted
Nov 7, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, within-subject placebo controlled study to evaluate the safety and efficacy of various doses of STP705 administered as intradermal Injection in subjects with hypertrophic scar. The goals are to determine the recommended Phase 2 dose, the pharmacokinetics and pharmacidynamics parameters, and conduct analysis of biomarkers common to the scar formation pathway.

Conditions

  • Hypertrophic Scar

Interventions

  • STP705Drug

    The Cotsiranib drug substance is composed of two siRNA oligonucleotides, targeting TGF-β1 and Cox-2 mRNA respectively, and formulated in nanoparticles with Histidine-Lysine co-Polymer (HKP) peptide at a ratio of 1:4 in mass weight (siRNA:peptide), which is further formulated into a dry powder drug product. The administration route would be intra-dermal injection.

  • PlaceboDrug

    Normal Saline

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Differences among the 3 dosage Groups in 24 Patients' appearance of the scar from baseline evaluated by Patient and Observer Scar Assessment Scale (POSAS)Time frame: 32 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • WCCT Global

    Cypress, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.